Methods of treatment of periodontal disease

• US 7,217,691 B2
• Filed: 03/27/2003
• Issued: 05/15/2007
• Est. Priority Date: 07/01/1986
• Status: Expired due to Fees

• Current Assignee: Genetics Institute LLC (Pfizer Inc.)
• Original Assignee: Genetics Institute LLC (Pfizer Inc.)
• Inventors: Wozney, John M., Wang, Elizabeth, Rosen, Vicki A.
• Primary Examiner(s): ROMEO, DAVID S
• Application Number:
  US10/397,214
• Publication Number:
  US 20040009916A1
• Time in Patent Office: 1,510 Days
• Field of Search: 514/12, 514/801, 530/350, 530/300, 562/589, 424/486
• US Class Current: 514/8.8
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61L 24/043 Mixtures of macromolecular materials
• CPC Class Codes: A61L 27/227 Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
• CPC Class Codes: C07K 14/51 Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00
• CPC Class Codes: Y10S 930/12 Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Abstract

Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

Claims

1. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein is encoded by a nucleic acid that hybridizes under stringent hybridization conditions (hybridization at 65°

C. in 6×

SSC, 0.01M EDTA, 5×

Denhardt'"'"'s solution, 0.5% SDS, 100 μ

g/ml denatured salmon sperm DNA, labelled DNA probe;

washing at 65°

C. in 0.2×

SSC, 0.1×

SDS) to the complement of SEQ ID NO;

1 or SEQ ID NO;

3, wherein the encoded BMP protein has the ability to induce formation of cartilage or bone or both.

2. The method of claim 1, wherein the pharmaceutical composition further comprises collagen.

3. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises the amino acid sequence of SEQ ID NO:

2 or SEQ ID NO;

4.

4. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises amino acids 299–

396 of SEQ ID NO;

4.

5. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises amino acids 32–

129 of SEQ ID NO;

2.

6. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:

1 or SEQ ID NO;

3.

7. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises the amino acid sequence encoded by nucleotides 1–

387 of SEQ ID NO;

1.

8. A method for treating peridontal disease in a patient in need of same comprising administering a pharmaceutical composition comprising an effective amount of a BMP-2 protein in a pharmaceutically acceptable vehicle, wherein the BMP-2 protein comprises the amino acid sequence encoded by nucleotides 356–

1543 of SEQ ID NO;

3.